HomeAI · summaries
Storia in 7 fonti
Alzheimer: remédio com novo alvo reduz em até 50% o declínio cognitivo em testes iniciais e avança para última fase de estudos
Medicamento experimental focado na proteína tau demonstrou diminuição inédita da patologia cerebral em estudo clínico de Fase 2
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
apnews.com
An experimental Alzheimer's drug shows some promise as researchers hunt new approaches
An experimental drug might help slow early Alzheimer's disease in a markedly different way than current treatments — by lowering the brain's production of a protein called tau.
- ·
abcnews.com
Experimental Alzheimer's drug shows some promise as researchers hunt new approaches
An experimental drug might help slow early Alzheimer's disease in a markedly different way than current treatments — by lowering the brain's production of a protein called tau
- ·
thestar.com
An experimental Alzheimer’s drug shows some promise as researchers hunt new approaches
WASHINGTON (AP) — An experimental drug might help slow early Alzheimer’s disease in a markedly different way than today’s treatments — by lowering levels of a brain protein called…
- ·
independent.co.uk
New experimental drug shows promise in slowing early Alzheimer’s
An experimental drug might help slow early Alzheimer's disease in a markedly different way than current treatments — by lowering the brain's production of a protein called tau
- ·
medpagetoday.com
Novel Alzheimer's Drug Targeting Tau Shows Promise in Mid-Stage Trial
Diranersen misses study's main goal but shows signs of cognitive benefit
- ·
fortune.com
New experimental Alzheimer's drug shows potential after study shows slower cognitive decline | Fortune
A study on Biogen's diranersen found it slowed cognitive decline and has promise in treating Alzheimer's disease, researchers found.
- ·
oglobo.globo.com
Alzheimer: remédio com novo alvo reduz em até 50% o declínio cognitivo em testes iniciais e avança para última fase de estudos
Medicamento experimental focado na proteína tau demonstrou diminuição inédita da patologia cerebral em estudo clínico de Fase 2